| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. | SVP, Chief Commercial Officer | Common Stock | 150K | $122K | $0.81 | Mar 9, 2023 | Direct |
| Aquestive Therapeutics, Inc. | SVP, Chief Commercial Officer | Common Stock | 1.45K | $1.17K | $0.81 | Mar 9, 2023 | Tasro Consulting, LLC 401(k) Plan, Kenneth Marshall Trustee, f/b/o Kenneth Marshall |
| Aquestive Therapeutics, Inc. | SVP, Chief Commercial Officer | Performance Stock Units | 75K | Aug 9, 2023 | Direct | ||
| Aquestive Therapeutics, Inc. | SVP, Chief Commercial Officer | Non-Qualified Stock Option (right to buy) | 40K | Nov 4, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | Aug 9, 2023 | 1 | $0 | 4 | Aug 9, 2023 | SVP, Chief Commercial Officer |
| AQST | Aquestive Therapeutics, Inc. | May 5, 2023 | 1 | $0 | 4 | May 5, 2023 | SVP, Chief Commercial Officer |
| AQST | Aquestive Therapeutics, Inc. | Mar 9, 2023 | 1 | $0 | 4 | Mar 9, 2023 | SVP, Chief Commercial Officer |
| AQST | Aquestive Therapeutics, Inc. | Nov 4, 2022 | 1 | $0 | 4 | Nov 8, 2022 | SVP, Chief Commercial Officer |
| AQST | Aquestive Therapeutics, Inc. | Mar 10, 2022 | 1 | $0 | 4 | Mar 14, 2022 | SVP, Chief Commercial Officer |